Hepatic Safety and Tolerability of Raltegravir among HIV Patients Coinfected with Hepatitis B And/Or C

Abstract

Background

Potential liver toxicity is an important consideration for antiretroviral selection among patients coinfected with HIV and viral hepatitis (B and/or C). We sought to describe the hepatic safety profile of raltegravir in this population.

Methods

Using data from HIV clinical cohorts at Johns Hopkins University and the University of North Carolina at Chapel Hill, we evaluated factors associated with liver enzyme elevations (LEEs) and calculated adverse event incidence rates for patients initiated on raltegravir-containing regimens prior to 1 January 2010. LEEs were graded according to Division of AIDS definitions.

Results

During the study period, 456 patients received raltegravir – of whom 36% were hepatitis-coinfected (138 HCV, 17 HBV, 11 HBV+HCV). Coinfected patients were more likely to have baseline abnormal LEEs and developed severe (grade 3–4) LEEs at a rate 3.4x that of HIV-monoinfected patients (95% CI 1.28, 9.61). Among all participants, the incidence rate for first occurrence of severe LEEs was 5 per 100 person-years (95% CI 3, 7). In adjusted analyses, coinfected patients had a 2.7-fold increased hazard of severe LEEs (95% CI 1.03, 7.04). 60% of severe abnormalities occurred within 6 months after starting raltegravir; the drug was discontinued in 3 (1.3%) coinfected patients and 18 (6.2%) monoinfected patients.

Conclusions

Compared with HIV-monoinfected patients, those with HIV–hepatitis coinfection are at increased hazard of developing LEEs on raltegravir, at a level similar to other antiretrovirals. Severe events were uncommon, rarely leading to raltegravir discontinuation. With appropriate monitoring, raltegravir-based therapy is safe in hepatitis-coinfected patients.

References

Markowitz

, Morales-Ramirez

J.O.

, Nguyen

B.Y.

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43: 509–515.

Iwamoto

, Wenning

L.A.

, Petry

A.S.

Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther 2008; 83: 293–299.

Steigbigel

R.T.

, Cooper

D.A.

, Kumar

P.N.

Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339–354.

Gatell

J.M.

, Katlama

, Grinsztejn

Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010; 53: 456–463.

Steigbigel

R.T.

, Cooper

D.A.

, Teppler

Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605–612.

Markowitz

, Nguyen

B.Y.

, Gotuzzo

Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125–133.

Markowitz

, Nguyen

B.Y.

, Gotuzzo

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52: 350–356.

Lennox

J.L.

, Dejesus

, Berger

D.S.

Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39–48.

Rockstroh

, Teppler

, Zhao

Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012; 13: 127–131.

10.

Moore

R.D.

Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17 Suppl 1: S38–S41.

11.

Napravnik

, Eron

J.J.

Jr. , McKaig

R.G.

, Heine

A.D.

, Menezes

, Quinlivan

Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006; 18 Suppl 1: S45–S50.

12.

Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events (version 1.0, December 2004; Clarification, August 2009). Washington, D.C.: National Institute for Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services; 2009. (Accessed 24 March 2014.) Available from http://rsc.tech-res.com/document/safetyandpharmacovigilance/table_for_grading_severity_of_adult_pediatric_adverse_events.pdf.

13.

Servoss

J.C.

, Kitch

D.W.

, Andersen

J.W.

, Reisler

R.B.

, Chung

R.T.

, Robbins

G.K.

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989–1999). J Acquir Immune Defic Syndr 2006; 43: 320–323.

14.

Vispo

, Mena

, Maida

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010; 65: 543–547.

15.

Macías

, Neukam

, Portilla

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2011; 66: 1346–1350.

16.

Weimer

L.E.

, Fragola

, Floridia

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. J Antimicrob Chemother 2013; 68: 193–199.

17.

Sulkowski

M.S.

, Thomas

D.L.

, Mehta

S.H.

, Chaisson

R.E.

, Moore

R.D.

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182–189.

18.

Martín-Carbonero

, Núñez

, Gonzalez-Lahoz

, Soriano

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003; 4: 115–120.

19.

Soriano

, Puoti

, Garcia-Gasco

Antiretroviral drugs and liver injury. AIDS 2008; 22: 1–13.

20.

Wit

F.W.

, Weverling

G.J.

, Weel

, Jurriaans

, Lange

J.M.

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23–31.

21.

Núñez

, Lana

, Mendoza

J.L.

, Martin-Carbonero

, Soriano

Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426–431.

22.

den Brinker

, Wit

F.W.

, Wertheim-van Dillen

P.M.

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895–2902.

23.

Macías

, Neukam

, Mallolas

Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. HIV Clin Trials 2012; 13: 61–69.

24.

Neukam

, Mira

J.A.

, Ruiz-Morales

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother 2011; 66: 2605–2614.

25.

Surgers

, Lacombe

Hepatoxicity of new antiretrovirals: a systematic review. Clins Res Hepatol Gastroenterol 2013; 37: 126–133.

26.

Jones

, Núñez

HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS. 2011; 6: 546–552.

27.

Puoti

, Torti

, Ripamonti

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32: 259–267.

28.

Sulkowski

M.S.

, Thomas

D.L.

, Chaisson

R.E.

, Moore

R.D.

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74–80.

29.

Naggie

, Sulkowski

M.S.

Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012; 142: 1324–1334.e3.

30.

de Kanter

C.T.

, Blonk

M.I.

, Colbers

A.P.

, Schouwenberg

B.J.

, Burger

D.M.

Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013; 56: 300–306.

31.

van Heeswijk

R.P.

, Beumont

, Kauffman

R.S.

, Garg

Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther 2013; 18: 553–560.

32.

Ouwerkerk-Mahadevan

, Sekar

, Simion

, Peeters

, Beaumont-Mauviel

M.D.

The pharmacokinetic interactions of the HCV protease inhibitor simeprevir (TMC435) with HIV antiretroviral agents in healthy volunteers. IDWeek. 17–21 October 2012, San Diego, CA, USA. Abstract 1618.

33.

Food and Drug Administration. Approval letter - Olysio (simeprevir). (Updated 5 December 2013. Accessed 10 December 2013.) Available from http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/205123Orig1s000ltr.pdf.

34.

Kirby

, Mathias

, Rossi

, Moyer

, Shen

, Kearney

B.P.

No clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers. 63rd Annual Meeting of the American Association for the Study of Liver Diseases. 9–12 November 2012, Boston, MA, USA. Abstract 24410.

35.

Food and Drug Administration. Approval letter - Sovaldi (sofosbuvir). (Updated 6 December 2013. Accessed 10 December 2013.) Available from http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204671Orig1s000ltr.pdf.